Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies

• Hoofdauteurs: Khalid Alhazzani (Auteur), Meshal Alsahli (Auteur), Ahmed Z Alanazi (Auteur), Mohammad Algahtani (Auteur), Ahmad A Alenezi (Auteur), Ali Alhoshani (Auteur), Mohammed Alqinyah (Auteur), Abdullah S. Alhamed (Auteur), Khaled Alhosaini (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2023-10-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Non-small cell lung carcinoma is a challenging disease worldwide. This study aims to determine whether combining erlotinib, an epidermal growth factor receptor (EGFR) inhibitor, with cabozantinib, a mesenchymal-epithelial transition factor (c-Met) inhibitor, would have an augmented therapeutic benef...